Topic
Small hairpin RNA
About: Small hairpin RNA is a research topic. Over the lifetime, 9279 publications have been published within this topic receiving 285471 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: Cisplatin is identified as a MAPK pathway-dependent inducer of ATF3, whose expression influences cisplatin's cytotoxic effects, and ATF3-/- murine embryonic fibroblasts were shown to be less sensitive to cis platin-induced cytotoxicity compared with ATF3+/+ MEFs.
83 citations
TL;DR: TGR-1202 is a dual PI3Kδ/CK1ε inhibitor, which may in part explain the clinical activity of TGR- 1202 in aggressive lymphoma not found with idelalisib.
83 citations
TL;DR: Heme oxygenase-1 is postulate as an important mediator of vGPCR-induced tumor growth and inhibition of intratumoral HO-1 activity by SnPP may be a potential therapeutic strategy, and targeted knock-down gene expression ofHO-1 by small hairpin RNA and chemical inhibition by tin protoporphyrin IX are suggested.
83 citations
TL;DR: It is demonstrated that an antiviral RNAi-based gene therapy on blood stem cells leads to HIV-1-resistant T cells in vivo, an important proof of concept in the clinical development of RNAi against HIV- 1.
Abstract: RNA interference (RNAi) gene therapy against HIV-1 by stable expression of antiviral short hairpin RNAs (shRNAs) can potently inhibit viral replication in T cells. Recently, a mouse model with a human immune system (HIS) was developed that can be productively infected with HIV-1. In this in vivo model, in which Rag-2(-/-)gamma(c)(-/-) mice are engrafted with human CD34(+)CD38(-) hematopoietic precursor cells, we evaluated an anti-HIV RNAi gene therapy. Human hematopoietic stem cells were transduced with a lentiviral vector expressing an shRNA against the HIV-1 nef gene (shNef) or the control vector. We observed normal development of the different cell subsets of the immune system. However, although initial transduction efficiencies were similar for both vectors, a reduced percentage of transduced human immune cells was observed for the shNef vector after establishment of the HIS in vivo. Further studies are required to fully evaluate the safety implications. When we infected the mature human CD4(+) T cells from the HIS mouse ex vivo with HIV-1, potent inhibition of viral replication was scored in shNef-expressing cells, confirming efficacy. When challenged with an shNef-resistant HIV-1 variant, equal replication was scored in control and shNef-expressing cells, confirming sequence-specificity of the RNAi therapy. We thus demonstrated that an antiviral RNAi-based gene therapy on blood stem cells leads to HIV-1-resistant T cells in vivo, an important proof of concept in the clinical development of RNAi against HIV-1.
83 citations
TL;DR: The results suggest that andrographolide attenuates TNFα-induced ICAM-1 expression at least partially through suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression, which is PI3K/Akt pathway-dependent.
83 citations